vs
Side-by-side financial comparison of Vyome Holdings, Inc (HIND) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $1.2M, roughly 1.0× Vyome Holdings, Inc). On growth, RELMADA THERAPEUTICS, INC. posted the faster year-over-year revenue change (13.0% vs -36.8%). Over the past eight quarters, RELMADA THERAPEUTICS, INC.'s revenue compounded faster (95.4% CAGR vs -24.1%).
Vyome Holdings, IncHINDEarnings & Financial Report
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for a range of dermatological conditions. Its product pipeline targets unmet medical needs related to acne, atopic dermatitis, and chronic fungal infections, with primary operations and market presence across North America and South Asia.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
HIND vs RLMD — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.3M |
| Net Profit | $-2.6M | — |
| Gross Margin | 48.2% | — |
| Operating Margin | -222.4% | -2130.6% |
| Net Margin | -211.8% | — |
| Revenue YoY | -36.8% | 13.0% |
| Net Profit YoY | -64.9% | — |
| EPS (diluted) | $-2.25 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.8M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $1.9M | — | ||
| Q4 23 | $2.0M | $1.3M | ||
| Q3 23 | $2.2M | $1.3M |
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $-547.8K | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — | ||
| Q4 23 | $-1.7M | — | ||
| Q3 23 | $-3.5M | $-22.0M |
| Q2 25 | 48.2% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | -118.6% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 57.7% | — | ||
| Q1 24 | 59.9% | — | ||
| Q4 23 | 92.9% | — | ||
| Q3 23 | 59.8% | — |
| Q2 25 | -222.4% | — | ||
| Q1 25 | -198.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -12.3% | — | ||
| Q2 24 | -104.5% | — | ||
| Q1 24 | -113.7% | — | ||
| Q4 23 | -95.7% | -2130.6% | ||
| Q3 23 | -180.0% | -1717.3% |
| Q2 25 | -211.8% | — | ||
| Q1 25 | 132.4% | — | ||
| Q4 24 | 160.0% | — | ||
| Q3 24 | -23.9% | — | ||
| Q2 24 | -81.2% | — | ||
| Q1 24 | -112.8% | — | ||
| Q4 23 | -85.7% | — | ||
| Q3 23 | -164.0% | -1665.0% |
| Q2 25 | $-2.25 | — | ||
| Q1 25 | $18.98 | — | ||
| Q4 24 | $-4355.36 | — | ||
| Q3 24 | $-1419.10 | — | ||
| Q2 24 | $-91.56 | — | ||
| Q1 24 | $-135.37 | — | ||
| Q4 23 | $-48.87 | $-0.84 | ||
| Q3 23 | $-59.36 | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-5.0M | $85.4M |
| Total Assets | — | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | $2.5M | — | ||
| Q4 24 | $101.9K | — | ||
| Q3 24 | $743.0K | — | ||
| Q2 24 | $12.0K | — | ||
| Q1 24 | $2.4M | — | ||
| Q4 23 | $4.5M | $96.3M | ||
| Q3 23 | $1.4M | $106.3M |
| Q2 25 | $-5.0M | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $-4.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q1 24 | $4.5M | — | ||
| Q4 23 | $-6.2M | $85.4M | ||
| Q3 23 | $3.1M | $100.7M |
| Q2 25 | — | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $-614.0K | — | ||
| Q1 24 | $8.2M | — | ||
| Q4 23 | $10.7M | $97.6M | ||
| Q3 23 | $7.8M | $109.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-10.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-2.5M | $-10.2M | ||
| Q3 23 | $-2.8M | $-11.6M |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.0% | — |
| Q2 25 | — | — | ||
| Q1 25 | -1.44× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
